Late Hematologic Recovery after CPX-351 Induction Chemotherapy in AML: Predictive Disease and Patient's Factors and Their Impact on Survival

被引：0

作者：

Rondoni, Michela ^{[1
]}

Minetto, Paola ^{[2
]}

Puglisi, Bruna ^{[3
]}

Saraceni, Francesco ^{[3
]}

Brunetti, Lorenzo ^{[4
]}

Mianulli, Anna Maria ^{[5
]}

Bocchia, Monica ^{[6
]}

Santoni, Adele ^{[6
]}

Riva, Carola ^{[7
]}

Giannini, Barbara ^{[8
]}

Monaco, Federica ^{[9
]}

Zannetti, Beatrice

Cellini, Claudia ^{[10
]}

Nicoletti, Annalisa ^{[8
]}

Valenti, Anna Maria ^{[8
]}

Capelli, Debora ^{[11
]}

Raspadori, Donatella ^{[12
]}

Olivieri, Attilio ^{[13
]}

Lanza, Francesco ^{[14
,15
]}

Graziano, Claudio

Tosi, Patrizia

Lemoli, Roberto Massimo ^{[16
]}

Guolo, Fabio ^{[17
]}

机构：

[1] AUSL Romagna, Hematol Unit Metropolitan Transplant Network, Ravenna, Italy

[2] IRCCS Osped Policlin San Martino, Clin Ematol, Dipartimento Oncol Ematol, Genoa, Italy

[3] Azienda Osped Univ Marche, Hematol & Stem Cell Transplant, Ancona, Italy

[4] Azienda Osped Univ Marche, Clin Ematol, Ancona, Italy

[5] AUSL Romagna, Hematol Unit, Infermi Hosp, Rimini, Italy

[6] Azienda Osped Univ Senese, UOC Ematol, Siena, Italy

[7] Univ Genoa, Dept Internal Med DiMI, Clin Hematol, Genoa, Italy

[8] Ctr Serv Lab Unico Area Vasta Romagna, Genet Med, Pievesestina Di Cesen, Cesena, Italy

[9] AUSL Romagna, Hematol Unit, Ravenna, Italy

[10] Osped Santa Maria Croci, AUSL Romagna, Clin Ematol, Ravenna, Italy

[11] Osped Riuniti Ancona, Clin Ematol, Azienda Osped Univ Marche, Ancona, Italy

[12] Univ Siena, Dept Med Sci Surg & Neurosci, Hematol, Siena, Italy

[13] Azienda Osped Univ Marche, Clin Ematol, Ancona, Italy

[14] Univ Bologna, Hematol Unit, Ravenna, Italy

[15] Univ Bologna, Metropolitan Romagna Transplant Network, Ravenna, Italy

[16] Univ Genoa, Dept Internal Med DiMI, Clin Hematol, Genoa, Italy

[17] IRCCS Osped Policlin San Martino, Genoa, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182993

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 36 条

[1] CPX-351 IN AML after failed induction with cytarabine and daunorubicin.
Lancet, J. E.
Feldman, E. J.
Cortes, J. E.
Hogge, D.
Tallman, M. S.
Kovacsovics, T.
Louie, A. C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[2] Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML
Murphy, Tracy
Zou, Jinfeng
Daher-Reyes, Georgina S.
Arruda, Andrea
Gupta, Vikas
McNamara, Caroline J.
Minden, Mark D.
Schimmer, Aaron D.
Sibai, Hassan
Yee, Karen W. L.
Korulla, Mariam
Stockley, Tracy
Kamel-Reid, Suzanne
Maze, Dawn
Tierens, Anne
Bratman, Scott, V
Schuh, Andre C.
Chan, Steven M.
[J]. BLOOD ADVANCES, 2019, 3 (15) : 2307 - 2311
[3] Safety and feasibility of outpatient induction chemotherapy with CPX-351 in selected older adult patients with newly diagnosed AML.
Kubal, Timothy Edward
Salamanca, Christopher
Komrokji, Rami S.
Sallman, David A.
Sweet, Kendra Lynn
Padron, Eric
List, Alan F.
Lancet, Jeffrey E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy
Feldman, Eric Jay
Lancet, Jeffrey E.
Kolitz, Jonathan E.
Hogge, Donna
Tallman, Martin S.
Goldberg, Stuart L.
Kovacsovics, Tibor
Louie, Arthur Chin
Cortes, Jorge E.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[5] Validation of AML-score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia
Schmucker, Abigail M.
Leiby, Benjamin E.
Wilde, Lindsay
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : E206 - E212
[6] Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations
Murphy, Tracy
Zou, Jinfeng
Daher-Reyes, Georgina S.
Gupta, Vikas
McNamara, Caroline J.
Minden, Mark D.
Schimmer, Aaron D.
Sibai, Hassan
Yee, Karen W. L.
Stockley, Tracy L.
Kamel-Reid, Suzanne
Maze, Dawn
Bratman, Scott
Schuh, Andre
Chan, Steven M.
[J]. BLOOD, 2018, 132
[7] Delayed Hematologic Recovery in AML Patients After Induction Chemotherapy is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations
Murphy, Tracy
Zhou, Jinfeng
Daher-Reyes, Georgina
Gupta, Vikas
McNamara, Caroline
Minden, Mark
Schimmer, Aaron
Sibai, Hassan
Yee, Karen
Stockley, Tracy
Kamel-Reid, Suzanne
Maze, Dawn
Bratman, Scott
Schuh, Andre
Tierens, Anne
Chan, Steven
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S229 - S230
[8] Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States
Kansal, Anuraag
Reifsnider, Odette
Todorova, Lora
Coughlan, Anna
Villa, Kathleen F.
[J]. BLOOD, 2018, 132
[9] CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia
Lee, Dasom
Asghari, Hannah H.
Deutsch, Yehuda E.
Chan, Onyee
Padron, Eric
Kuykendall, Andrew T.
List, Alan F.
Komrokji, Rami S.
Fernandez, Hugo F.
Lancet, Jeffrey E.
Sallman, David A.
Sweet, Kendra L.
Talati, Chetasi
[J]. BLOOD, 2019, 134
[10] The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML
Lin, Tara L.
Cortes, Jorge E.
Newell, Laura F.
Ritchie, Ellen K.
Stuart, Robert K.
Strickland, Stephen A.
Hogge, Donna
Solomon, Scott R.
Stone, Richard M.
Bixby, Dale L.
Kolitz, Jonathan E.
Schiller, Gary J.
Wieduwilt, Matthew J.
Ryan, Daniel H.
Ryan, Robert
Chiarella, Michael
Louie, Arthur C.
Uy, Geoffrey L.
[J]. BLOOD, 2018, 132

← 1 2 3 4 →